ES2627043T3 - Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa - Google Patents

Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa Download PDF

Info

Publication number
ES2627043T3
ES2627043T3 ES09763477.8T ES09763477T ES2627043T3 ES 2627043 T3 ES2627043 T3 ES 2627043T3 ES 09763477 T ES09763477 T ES 09763477T ES 2627043 T3 ES2627043 T3 ES 2627043T3
Authority
ES
Spain
Prior art keywords
cells
disease
alpha
cell therapy
fucoslitransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09763477.8T
Other languages
English (en)
Inventor
Len Miller
Lynnet Koh
Thomas E. Ichim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targazyme Inc
Original Assignee
Targazyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targazyme Inc filed Critical Targazyme Inc
Application granted granted Critical
Publication of ES2627043T3 publication Critical patent/ES2627043T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01065—3-Galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (2.4.1.65), i.e. alpha-1-3 fucosyltransferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

Celulas fucosiladas T para su uso en el injerto en un paciente en necesidad del mismo mediante la administracion de las celulas T fucosiladas al paciente, en el que las celulas T fucosiladas se obtienen por: (a) proporcionar celulas T de una poblacion celular expandida ex vivo; y (b) modificar dichas celulas T, poniendo en contacto dichas celulas T con 1,3-fucosiltransferasa VI alfa y/o 1,3- fucosiltransferasa VII alfa para proporcionar las celulas T fucosiladas.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
[0060] En ciertos aspectos, el paciente en necesidad de tratamiento con una población de células sufre de una
condición seleccionada del grupo que consiste en: una leucemia aguda, una leucemia crónica, un síndrome
mielodisplásico, un trastorno de células madre, un trastorno mieloproliferativo, un trastorno linfoproliferativo, un
trastorno de los fagocitos, un trastorno histiocítico, una enfermedad lisosomal de almacenamiento, un trastorno del
5 sistema inmunitario congénito, una anomalía de eritrocitos heredada, una anormalidad de plaquetas hereditaria, un
trastorno de las células de plasma, un tumor y una enfermedad autoinmune. En ciertos aspectos, el paciente en
necesidad de tratamiento con una población de células sufre de una condición seleccionada del grupo que consiste
en: enfermedades arteriales periféricas, lesiones de extremidad isquémica, diabetes, enfermedad cardíaca,
enfermedad hepática, enfermedad de los huesos, distrofia muscular, enfermedad de Alzheimer, esclerosis lateral 10 amiotrófica, esclerosis múltiple, enfermedad de Parkinson, lesión de la médula espinal, apoplejía e infertilidad. Otros
ejemplos de las condiciones descritas anteriormente se exponen en la Tabla I a continuación.
Tabla I 15
20
25
30
35
40
45
50
55
60
Leucemias agudas
Leucemias crónicas
Leucemia aguda bifenotípica
Leucemia linfocítica crónica (LLC)
Leucemia linfocítica aguda (LLA) Leucemia
Leucemia mielógena crónica (CML)
mielógena aguda (LMA)
Leucemia mielógena crónica juvenil
Leucemia aguda indiferenciada
(JCML) Leucemia mielomonocítica juvenil (LMMJ)
Síndromes mielodisplásicos
Trastornos de células madre
Amiloidosis
Anemia aplástica (severa)
Leucemia mielomonocítica crónica (LMMC)
Congénita citopenia
Anemia refractaria (RA)
Disqueratosis congénita
Anemia refractaria con exceso de blastos (AREB)
Anemia de Fanconi
Anemia refractaria con exceso de blastos en
Hemoglobinuria paroxística nocturna
transformación (AREB-T)
(PNH)
Anemia refractaria con sideroblastos en anillo
(ARSA)
Trastornos mieloproliferativos Mielofibrosis aguda Metaplasia mieloide agnogénica (mielofibrosis) Trombocitemia esencial Policitemia vera
Trastornos linfoproliferativos Enfermedad de Hodgkin Linfoma no de Hodgkin Leucemia prolinfocítica
Trastornos de los fagocitos
Trastornos histiocitarios
Síndrome de Chediak-Higashi
Linfohistiocitosis eritrofagocitaria
Enfermedad de granulomatosa crónica
familial
Deficiencia de actina de neutrófilos
Hemofagocitosis
Disgenesias reticulares
Histiocitosis-X Histiocitosis de células de Langerhans
Enfermedades de almacenamiento lisosomal
Trastornos del sistema inmunológico congénito (heredados)
Adrenoleucodistrofia
Manosidosis Alfa
Ausencia de células T y B SCID
Enfermedad de Gaucher
Ausencia de células T, células B
Síndrome de Hunter (MPS-II)
normales SCID
Síndrome de Hurler (MPS-IH)
Ataxia-Telangiectasia
Enfermedad de Krabbe
Síndrome de infocito desnudo
Syndrome de Maroteaux-Lamy (MPS-VI)
Inmunodeficiencia variable común
Leucodistrofia Metacromática
Síndrome de DiGeorge
Síndrome de Morquio (MPS-IV)
Síndrome de Kostmann Deficiencia de adhesión leucocitaria
Mucolipidosis II (enfermedad de células I)
Síndrome de Omenn
Mucopolisacaridosis (MPS)
inmunodeficiencia severa combinada
Enfermedades de Niemann-Pick
(SCID)
Síndrome de Sanfilippo (MPS-III)
SCID de deficiencia de deaminasa de
Síndrome de Scheie (MPS-IS)
adenosina
Síndrome de Sly, Deficiencia de beta-
Síndrome de Wiskott-Aldrich
glucuronidasa (MPS-VII)
Trastorno linfoproliferativo ligado a X
Enfermedad de Wolman
10
5
15
25
35
45
Anomalías heredadas de eritrocitos Talasemia mayor beta Anemia Blackfan-Diamond Aplasia de glóbulos rojos puros Enfermedad de células falciformes
Otros trastornos hereditarios Hipoplasia de cartílago-pelo Lipofuscinosis ceroide Porfiria eritropoyética congénita Trombastenia de Glanzmann Síndrme de Lesch-Nyhan Osteopetrosis Enfermedad de Sandhoff
Anomalías plaquetarias hereditarias
Trastornos de células plasmáticas
Amegacariocitosis/trombocitopenia congénita
Mieloma múltiple Leucemia de células plasmáticas Macroglobulinemia de Waldenstrom
Otras malignidades
Enfermedades autoinmunes
Tumores cerebrales
Esclerosis múltiple
Sarcoma de Ewing
Artritis reumatoide
Neuroblastoma
Lupus Eritematoso Sistémico
Cáncer de ovario
Diabetes Mellitus
Carcinoma de células renales
Enfermedades inflamatorias del intestino
Cáncer de pulmón de células pequeñas
Cáncer testicular
Otras aplicaciones Trasplantes de médula ósea Enfermedad cardíaca (infarto de miocardio), ya sea solo o en combinación con agentes potenciadores, tales como eritropoyetina Enfermedad de hígado Distrofia muscular Enfermedad de Alzheimer Enfermedad de Parkinson Lesión de la médula espinal Infarto, ya sea solo o en combinación con agentes potenciadores
tales como eritropoyetina Enfermedad vascular periférica Trauma a la cabeza Poblaciones de células madre y progenitoras expandidas ex vivo e in vivo Aplicación de fertilización in vitro y situaciones de rescate hematopoyéticas mejoradas (quimio intenso/radiación) Células madre y células progenitoras derivadas de diversas fuentes de tejidos Aplicación en seres humanos y animales Regeneración de extremidades, solo o en combinación con agentes de mejora
[0061] La terapia celular es también deseable para el tratamiento de enfermedades en las que se solicita el sistema inmune para ser mejorada. Una forma particular de la terapia celular implica la expansión de células T que poseen una especificidad para un antígeno distinto, por ejemplo un antígeno de tumor. En otros tipos de terapia celular, se generan las células T, y se reprograman ex vivo para la capacidad de matar a una pluralidad de células que expresan una pluralidad de marcadores. Los ejemplos de tal terapia celular incluyen la expansión de células T
55 autólogas con IL-2, la estimulación con lisados de células tumorales, y la reintroducción de dichas células en el paciente.
[0062] Por otra parte, la terapia celular se puede realizar en situaciones donde se desea la supresión de una respuesta inmune. En tales situaciones es deseable la expansión de las células, tales como CD4 + CD25 + células T reguladoras, ya que estas células son capaces de inhibir las respuestas inmunitarias de una manera específica de antígeno. Los métodos para la expansión de estas células son comúnmente conocidas e incluyen el uso de citoquinas tales como TGF-b.
[0063] Un problema en guiado de médula ósea es que los receptores en las células endoteliales para los ligandos
65 glicosilados de células circulantes se expresan constitutivamente. Estos receptores, tales como selectinas P y E, inducen numerosas actividades después de interactuar con las células, incluyendo la causación de apoptosis o
11
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
    imagen2
ES09763477.8T 2008-06-09 2009-06-09 Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa Active ES2627043T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6008408P 2008-06-09 2008-06-09
US60084P 2008-06-09
PCT/US2009/046800 WO2009152187A1 (en) 2008-06-09 2009-06-09 Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase

Publications (1)

Publication Number Publication Date
ES2627043T3 true ES2627043T3 (es) 2017-07-26

Family

ID=41417098

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09763477.8T Active ES2627043T3 (es) 2008-06-09 2009-06-09 Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa

Country Status (4)

Country Link
US (1) US20110091434A1 (es)
EP (1) EP2300599B1 (es)
ES (1) ES2627043T3 (es)
WO (1) WO2009152187A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
EP2968646B1 (en) 2013-03-13 2019-05-29 AlloSource Fascia fibrous compositions and methods for their use and manufacture
WO2014150784A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
US9795707B2 (en) 2013-12-06 2017-10-24 Allosource Methods of drying sheets of donor-provided human birth tissue
CN114540266A (zh) * 2014-07-07 2022-05-27 塔尔加泽梅股份有限公司 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
CN110475571B (zh) 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
IL322061A (en) * 2023-01-13 2025-09-01 The Brigham And Womens Hospital Compositions and methods for identifying and isolating human hematopoietic stem and progenitor cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331658B1 (en) * 1993-04-20 2001-12-18 Integris Baptist Medical Center, Inc. Genetically engineered mammals for use as organ donors
US20060210558A1 (en) * 2000-10-18 2006-09-21 Robert Sackstein Hematopoietic cell selectin ligand polypeptides and methods of use thereof
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US7332334B2 (en) * 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
CA2640087A1 (en) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
AU2007254777B2 (en) * 2006-06-02 2014-02-20 Robert Sackstein Compositions and methods for modifying cell surface glycans

Also Published As

Publication number Publication date
EP2300599B1 (en) 2017-03-01
US20110091434A1 (en) 2011-04-21
WO2009152187A1 (en) 2009-12-17
EP2300599A1 (en) 2011-03-30
EP2300599A4 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
JP2018184448A5 (es)
Bellantuono Haemopoietic stem cells
Bozhilov et al. In vitro human haematopoietic stem cell expansion and differentiation
Park et al. Hematopoietic stem cell expansion and generation: the ways to make a breakthrough
Kindwall-Keller et al. Umbilical cord blood: The promise and the uncertainty
Leung Use of NK cell activity in cure by transplant
Costa et al. Origin of blood cells and HSC production in the embryo
US10370643B2 (en) LILRB2 and notch-mediated expansion of hematopoietic precursor cells
Tung et al. Ex vivo expansion of umbilical cord blood for transplantation
EP2300599B1 (en) Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
JP2008517948A5 (es)
Tanner et al. Humanized mice as a model to study human hematopoietic stem cell transplantation
Farahbakhshian et al. Angiopoietin-like protein 3 promotes preservation of stemness during ex vivo expansion of murine hematopoietic stem cells
JP2019507596A5 (es)
JP2024016037A5 (es)
Kanji et al. Plasticity and maintenance of hematopoietic stem cells during development
Watts et al. Hematopoietic stem cell expansion and gene therapy
Bin et al. Against all odds: The road to success in the development of human immune reconstitution mice
Biancotti et al. Increasing hematopoietic stem cell yield to develop mice with human immune systems
Barcia Durán et al. Haematopoietic stem cell reprogramming and the hope for a universal blood product
Leung et al. All-trans retinoic acid (ATRA) enhances maintenance of primitive human hematopoietic progenitors and skews them towards myeloid differentiation in a stroma-noncontact culture system
CA2703428A1 (en) Pooled cord blood units
DE102012207453B4 (de) Humanisierte Mäuse ohne Konditionierung
Lim et al. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells
Arias Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) Cell Therapy in Acute Myeloid Leukemia: A Systematic Review of the Literature